SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 20.45 |
| Enterprise Value ($M) | -17.13 |
| Book Value ($M) | 61.26 |
| Book Value / Share | 0.99 |
| Price / Book | 0.33 |
| NCAV ($M) | 37.66 |
| NCAV / Share | 0.61 |
| Price / NCAV | 0.54 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.75 |
| Return on Assets (ROA) | -0.46 |
| Return on Equity (ROE) | -0.62 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 4.07 |
| Current Ratio | 4.07 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 78.81 |
| Assets | 102.41 |
| Liabilities | 41.15 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | -65.17 |
| Net Income | -64.77 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -47.96 |
| Cash from Investing | 54.95 |
| Cash from Financing | 8.87 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Lynx1 Capital Management LP | 15.00 | 9.85 | |
| 13D/A | Orbimed Advisors Llc | 12.00 | -7.83 | |
| 13G/A | Erste Asset Management GmbH | 4.42 | ||
| 13G | Vestal Point Capital, LP | 9.90 | ||
| 13D/A | Versant Venture Capital VI, L.P. | 0.00 | -100.00 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K | ||
| Y UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| Y UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| Y UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 18,181 | 156,955 | 11.58 | |
| 97,530 | 266,232 | 36.63 | |
| 20,102 | 143,271 | 14.03 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| ORMP – Oramed Pharmaceuticals Inc. | OTLK – Outlook Therapeutics, Inc. |
| PALI – Palisade Bio, Inc. | PCSA – Processa Pharmaceuticals, Inc. |
| PDSB – PDS Biotechnology Corporation |
Financial data and stock pages provided by
Fintel.io